
Jan 12 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:
HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATION
HARMONY BIOSCIENCES Q4 PRELIM UNAUDITED NET PRODUCT REVENUE $243 MILLION
HARMONY BIOSCIENCES: WAKIX NET REVENUE PROJECTED BETWEEN $1.0 BILLION - $1.04 BILLION FOR 2026